Impact of Rivastigmine Patch and Capsules on Activities of Daily Living in Alzheimer’s Disease
| Autor: | George T. Grossberg, Jason T. Olin, Xiangyi Meng |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Time Factors Activities of daily living Transdermal patch Phenylcarbamates Administration Oral Transdermal Patch Capsules Rivastigmine Disease Double-Blind Method Alzheimer Disease Activities of Daily Living Humans Medicine In patient Prospective Studies Aged Aged 80 and over business.industry General Neuroscience Middle Aged Lower incidence Psychiatry and Mental health Clinical Psychology Neuroprotective Agents Treatment Outcome Anesthesia Female Geriatrics and Gerontology business medicine.drug |
| Zdroj: | American Journal of Alzheimer's Disease & Other Dementiasr. 26:65-71 |
| ISSN: | 1938-2731 1533-3175 |
| DOI: | 10.1177/1533317510391240 |
| Popis: | Background: Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer’s disease (AD). Methods: Post hoc analysis of a 24-week, prospective, international, randomized, double-blind, placebo- and active-controlled trial. Patients (n = 892) with probable AD received rivastigmine transdermal patches (9.5 mg/24 hours [10 cm2]), rivastigmine capsules (6 mg twice daily), or placebo, and impact on activities of daily living (ADLs) was assessed utilizing 3 subscales: basic, high-level function, and autonomy. Results: At week 24, both rivastigmine groups demonstrated significantly superior performance in Alzheimer’s Disease Cooperative Study—Activities of Daily Living (ADCS-ADL) Total Score versus placebo (rivastigmine patch, P = .013; capsules, P = .039). Overall, both rivastigmine formulations provided benefits in ADL subscales. For basic ADLs, rivastigmine capsules performed significantly better than placebo (P = .012). For high-level function ADLs, rivastigmine patch performed better than placebo (P = .056). For autonomy ADLs, rivastigmine patch performed significantly better than placebo (P = .017). Conclusion: Rivastigmine patches and capsules provide significant effects in both total and subscale ADLs in patients with probable AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|